



Product	Elinzanetant (BAY3427080)
Swissmedic approval date:	August 5, 2025
Swissmedic approval ID	69917

Bayer study ID	Study title	WS direct link
21651	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	https://s3.amazonaws.com/ctr-bsp-7261/21651/d2ca5695-688e-4d2a-a610-90f3664b17b3/85b802db-0aee-4b0d-a8ee-773f9034171f/21651_Study_Synopsis_CTP-v3.pdf
21652	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	https://s3.amazonaws.com/ctr-bsp-7261/21652/360af6f8-5cb7-4bf8-9165-138cb3fcb475/b66c98ff-026c-49bc-a515-22832e17c639/21652_Study_Synopsis_CTP-v3.pdf
21668	BAY3427080, hepatic impairment	https://s3.amazonaws.com/ctr-bsp-7261/21668/53119866-6daf-4608-ad6d-425032a3deb4/6662c754-aeb6-40c4-8c31-d2795b7fd807/21668_Websynopsis_2023-02-01-v2.pdf
21669	Open-label study to evaluate the pharmacokinetics, safety, and tolerability of elinzanetant in participants with impaired renal function in comparison to matched controls with normal renal function	https://s3.amazonaws.com/ctr-bsp-7261/21669/02e87a83-7b0c-423f-9f53-fe0135966f28/8cc227da-a149-4403-b4f4-e237bab6228c/21669_Study_Synopsis_CTP-v2.pdf
21681	PK and Safety of NT-814 in postmenopausal women	https://clinicaltrials.bayer.com/study/21681
21686	Phase 2 Dose finding, Efficacy and safety	https://s3.amazonaws.com/ctr-bsp-7261/21686/9eaa3efc-e401-47b8-84ae-8db413334610/efea4e35-c8ec-48d1-b9e6-031751a75ce4/21686_Study_Synopsis_CTP-v3.pdf
21810	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women	https://s3.amazonaws.com/ctr-bsp-7261/21810/7c9a4618-b24c-4b13-a7b9-66c9f05f11d4/d07907d4-948e-4978-b03a-a59e6f4fd649/21810_Study_Synopsis_CTP-v4.pdf